B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma.

摘要: During the past two decades there has been a major shift in choice of agents to treat multiple myeloma, whether newly diagnosed or relapsed/refractory stage. The introduction new drug classes, such as proteasome inhibitors, immunomodulators, and anti-CD38 anti-SLAMF7 monoclonal antibodies, coupled with autologous stem cell transplantation, approximately doubled disease's five-year survival rate. However, this positive news is tempered by realization that these measures are not curative patients eventually relapse and/or become resistant drug's effects. Thus, need discover newer myeloma-driving molecular markers develop innovative drugs designed precisely regulate actions putative targets. B maturation antigen (BCMA), which found almost exclusively on surfaces malignant plasma cells exclusion other types, including their normal counterparts, emerged specific target interest regard. Immunotherapeutic have at forefront research block BCMA activity. These encompass conjugate belantamab mafodotin; bispecific T-cell engager strategies exemplified AMG 420; chimeric receptor (CAR) therapeutics include idecabtagene vicleucel (bb2121) JNJ-68284528.